Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on the 18th-20th November 2019 in London, UK. The global ophthalmic drug market size is ...

Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of USD 36 million in the U.S.

This new commercial leadership, along with investments in data management and human resources, will advance how Ora ensures a ...

for its Abbreviated New Drug Application for loteprednol etabonate ophthalmic gel, 0.38%, to market a generic equivalent of Lotemax SM ophthalmic gel of Bausch & Lomb Inc. Lupin is the exclusive first ...

Therefore, practitioners have had to prescribe many of these ophthalmic preparations empirically. In 1997, the U.S. Congress enacted a new law providing marketing incentives for pediatric drug ...

The Food and Drug Administration has given Lupin a tentative nod for two new generics. The first medication is loteprednol etabonate ophthalmic gel, 0.38%, which is a generic of Bausch & Lomb’s ...

KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc.

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...